JP2010527952A - Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物 - Google Patents

Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物 Download PDF

Info

Publication number
JP2010527952A
JP2010527952A JP2010508773A JP2010508773A JP2010527952A JP 2010527952 A JP2010527952 A JP 2010527952A JP 2010508773 A JP2010508773 A JP 2010508773A JP 2010508773 A JP2010508773 A JP 2010508773A JP 2010527952 A JP2010527952 A JP 2010527952A
Authority
JP
Japan
Prior art keywords
acid
ppar
group
diabetes
carnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010508773A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527952A5 (https=
Inventor
メノッティ・カルヴァーニ
ステファニア・ディドディオ
パオラ・ベナッティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2010527952A publication Critical patent/JP2010527952A/ja
Publication of JP2010527952A5 publication Critical patent/JP2010527952A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2010508773A 2007-05-24 2008-04-28 Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物 Withdrawn JP2010527952A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108801 2007-05-24
PCT/EP2008/055171 WO2008141897A1 (en) 2007-05-24 2008-04-28 Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists

Publications (2)

Publication Number Publication Date
JP2010527952A true JP2010527952A (ja) 2010-08-19
JP2010527952A5 JP2010527952A5 (https=) 2011-06-16

Family

ID=38668873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508773A Withdrawn JP2010527952A (ja) 2007-05-24 2008-04-28 Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物

Country Status (10)

Country Link
US (1) US20100305204A1 (https=)
EP (1) EP2162127A1 (https=)
JP (1) JP2010527952A (https=)
KR (1) KR20100017460A (https=)
CN (1) CN101677983B (https=)
AU (1) AU2008253134A1 (https=)
BR (1) BRPI0812306A2 (https=)
CA (1) CA2687154A1 (https=)
MX (1) MX2009012429A (https=)
WO (1) WO2008141897A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
KR102072075B1 (ko) * 2018-06-21 2020-01-31 울산과학기술원 TRIM25을 유효성분으로 함유하는 PPARγ 분해용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
AU2192000A (en) * 1998-12-17 2000-07-03 Mindset Biopharmaceuticals (Usa) Inc. Increasing brain glucose utilization
CN1812988A (zh) * 2003-05-13 2006-08-02 斯索恩有限公司 制备噻唑烷二酮衍生物的方法及其化合物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient

Also Published As

Publication number Publication date
WO2008141897A1 (en) 2008-11-27
CA2687154A1 (en) 2008-11-27
US20100305204A1 (en) 2010-12-02
EP2162127A1 (en) 2010-03-17
AU2008253134A1 (en) 2008-11-27
CN101677983A (zh) 2010-03-24
KR20100017460A (ko) 2010-02-16
BRPI0812306A2 (pt) 2014-11-25
CN101677983B (zh) 2012-12-26
MX2009012429A (es) 2009-12-09

Similar Documents

Publication Publication Date Title
JP5249388B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
US20080249168A1 (en) Pharmaceutical composition for gout
WO2008058355A2 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
WO2008058358A2 (en) Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.
JP2010527952A (ja) Ｐｐａｒ−ガンマアゴニストの使用に起因する有害作用の防止に有用な組成物
JP5697337B2 (ja) ２型糖尿病の処置に有用な組成物
DK2136798T3 (en) Compositions useful in the prevention of type 2 diabetes and complications associated therewith in pre-diabetic patients with insulin resistance
JPWO2005092349A1 (ja) インスリン抵抗性改善剤
HK1139038A (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
JP2002220345A (ja) 脂肪肝改善剤
JP2004532866A (ja) ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用
JP7344422B2 (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
Hydrochloride et al. Pr NRA-Metformin Tablets
Metformin Hydrochloride Tablets et al. Pr METFORMIN TABLETS
JP5230195B2 (ja) 心血管疾患の治療のためのｌ−カルニチンおよびグルコースの使用
Metformin Tablets et al. Pr RIVA-METFORMIN
Agent PrMYLAN-METFORMIN
Tablets et al. Pr ACT METFORMIN
HK1135030B (en) Composition useful for the treatment of type 2 diabetes
Tablets et al. Pr AURO-METFORMIN
HK1113542B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1166003B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110426

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130204